Xinna Zhou

853 total citations
38 papers, 659 citations indexed

About

Xinna Zhou is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Xinna Zhou has authored 38 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in Xinna Zhou's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Immune Cell Function and Interaction (12 papers). Xinna Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers) and Immune Cell Function and Interaction (12 papers). Xinna Zhou collaborates with scholars based in China, United States and Ethiopia. Xinna Zhou's co-authors include Jun Ren, H. Kim Lyerly, Xiaoli Wang, Michael A. Morse, Amy Hobeika, Guohong Song, Shuo Wang, Yanhua Yuan, Huabing Yang and Lijun Di and has published in prestigious journals such as Scientific Reports, Clinical Cancer Research and Pain.

In The Last Decade

Xinna Zhou

36 papers receiving 645 citations

Peers

Xinna Zhou
Yongsheng Yang China
Siu W. Lam Netherlands
Daan P. Hurkmans Netherlands
Theodore S. Nowicki United States
Yihe Yan China
Xiaojuan Wu China
Jesse J. Balic Australia
Xiaoqin Yang China
Yifeng He China
Shengling Fu China
Yongsheng Yang China
Xinna Zhou
Citations per year, relative to Xinna Zhou Xinna Zhou (= 1×) peers Yongsheng Yang

Countries citing papers authored by Xinna Zhou

Since Specialization
Citations

This map shows the geographic impact of Xinna Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinna Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinna Zhou more than expected).

Fields of papers citing papers by Xinna Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinna Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinna Zhou. The network helps show where Xinna Zhou may publish in the future.

Co-authorship network of co-authors of Xinna Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xinna Zhou. A scholar is included among the top collaborators of Xinna Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinna Zhou. Xinna Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Congcong, Peng Shu, Lina Hu, et al.. (2025). Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy. Infectious Agents and Cancer. 20(1). 23–23.
2.
Wang, Shuo, Fang Tong, Xiaoguang Qiu, et al.. (2021). Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. International Journal of Radiation Oncology*Biology*Physics. 111(2). 479–490. 5 indexed citations
3.
Wang, Xiaoli, Shuo Wang, Michael A. Morse, et al.. (2019). Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis. 47(4). 505–511. 8 indexed citations
4.
Wang, Shuo, Guoliang Qiao, Xiaoli Wang, et al.. (2019). Functional CD3+CD8+PD1− T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. Clinical Breast Cancer. 19(5). e617–e623. 9 indexed citations
5.
Zhou, Xinna, Guoliang Qiao, Jun Ren, et al.. (2019). Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. Pain. 161(1). 127–134. 10 indexed citations
6.
Qiao, Guoliang, Xiaoli Wang, Lei Zhou, et al.. (2018). Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clinical Cancer Research. 25(5). 1494–1504. 52 indexed citations
7.
Jiang, Ni, Guoliang Qiao, Xiaoli Wang, et al.. (2017). Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research. 23(17). 5066–5073. 64 indexed citations
8.
Zhou, Xinna, Guoliang Qiao, Xiaoli Wang, et al.. (2017). CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer Chemotherapy and Pharmacology. 81(2). 365–372. 8 indexed citations
9.
Song, Qingkun, Jun Ren, Xinna Zhou, et al.. (2017). Circulating CD8+CD28− suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. Cytotherapy. 20(1). 126–133. 21 indexed citations
10.
Chen, Feng, Menghan Yang, Qingkun Song, et al.. (2017). Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients. Molecular and Clinical Oncology. 7(5). 903–910. 9 indexed citations
11.
Zhou, Xinna, Jing Yu, Wenmiao Wang, et al.. (2015). A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients. SpringerPlus. 4(1). 803–803. 15 indexed citations
12.
Song, Qingkun, Xinna Zhou, Jing Yu, et al.. (2015). The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. Scientific Reports. 5(1). 16775–16775. 8 indexed citations
13.
Zhao, Yanjie, Ni Jiang, Qingkun Song, et al.. (2015). Continuous DC-CIK Infusions Restore CD8+Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments. Asian Pacific Journal of Cancer Prevention. 16(6). 2419–2423. 9 indexed citations
14.
Huang, Hongyan, Yanbin Zhang, Xiaoli Wang, et al.. (2015). [Nuclear protein 1 knockdown inhibits proliferation and migration of HepG2 cells].. PubMed. 31(6). 782–6. 3 indexed citations
15.
16.
Zhou, Xinna. (2012). Development of drug induced liver injury in anti-tumor treatment. 1 indexed citations
17.
Liang, Xu, Jie Zhang, Xinna Zhou, et al.. (2012). Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clinical & Translational Oncology. 15(4). 331–334. 18 indexed citations
18.
Ma, Bo, Hanfang Jiang, Jun Jia, et al.. (2012). Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clinical & Translational Oncology. 14(10). 764–773. 25 indexed citations
19.
Di, Lijun, Jun Jia, Jing Yu, et al.. (2012). Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clinical & Translational Oncology. 14(9). 675–681. 16 indexed citations
20.
Wang, Zheng, Xu Liang, Jing Yu, et al.. (2012). Non‐genetic risk factors and predicting efficacy for docetaxel–drug‐induced liver injury among metastatic breast cancer patients. Journal of Gastroenterology and Hepatology. 27(8). 1348–1352. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongsheng Yang Breakdown of academic impact, for papers by Siu W. Lam Breakdown of academic impact, for papers by Daan P. Hurkmans Breakdown of academic impact, for papers by Theodore S. Nowicki Breakdown of academic impact, for papers by Yihe Yan Breakdown of academic impact, for papers by Xiaojuan Wu Breakdown of academic impact, for papers by Jesse J. Balic Breakdown of academic impact, for papers by Xiaoqin Yang Breakdown of academic impact, for papers by Yifeng He Breakdown of academic impact, for papers by Shengling Fu
Rankless by CCL
2026